
## Kenichi Kaida

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6242764/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An Atypical Phenotype of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Associated with Ocular Palsy, IgM-anti Ganglioside Antibody, and Fever-induced Recurrence. Internal Medicine, 2022, 61, 1247-1252.	0.3	3
2	Morphological characterization of cholinergic partition cells: A transmitter-specific tracing study by Cre/lox-dependent viral gene expression. Annals of Anatomy, 2022, 240, 151857.	1.0	1
3	Cholesterol-added antigens can enhance antiglycolipid antibody activity: Application to antibody testing. Journal of Neuroimmunology, 2021, 356, 577580.	1.1	1
4	Unique HLA haplotype associations in IgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy. Journal of Neuroimmunology, 2020, 339, 577139.	1.1	18
5	Association of variability in antibody binding affinity with a clinical course of anti-MAG neuropathy. Journal of Neuroimmunology, 2020, 339, 577127.	1.1	2
6	Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. JMIR Research Protocols, 2020, 9, e17117.	0.5	23
7	Intrathecal cytokine profile in neuropathy with antiâ€neurofascin 155 antibody. Annals of Clinical and Translational Neurology, 2019, 6, 2304-2316.	1.7	11
8	Guillain–Barré Syndrome. Advances in Experimental Medicine and Biology, 2019, 1190, 323-331.	0.8	25
9	Inflammatory myopathy with myasthenia gravis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e535.	3.1	33
10	A Japanese male with a novel ANO5 mutation with minimal muscle weakness and muscle pain till his late fifties. Neuromuscular Disorders, 2017, 27, 477-480.	0.3	8
11	Markers for Guillainâ€Barré syndrome with poor prognosis: a multiâ€center study. Journal of the Peripheral Nervous System, 2017, 22, 433-439.	1.4	46
12	Clinicopathologic features of myositis patients with CD8-MHC-1 complex pathology. Neurology, 2017, 89, 1060-1068.	1.5	29
13	Repeated treatments with rituximab in a patient with amyloid-like I <scp>g</scp> M deposition neuropathy. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e220.	3.1	2
14	Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e290.	3.1	71
15	lgC4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: Clinical significance and diagnostic utility of a conventional assay. Journal of Neuroimmunology, 2016, 301, 16-22.	1.1	70
16	A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS). JMIR Research Protocols, 2016, 5, e210.	0.5	18
17	Antibodies to glycoconjugates in autoimmune neuropathies. Clinical and Experimental Neuroimmunology, 2015, 6, 387-394.	0.5	7
18	Neuromyelitis optica overlapping systemic sclerosis with anti-centromere antibodies. Journal of the Neurological Sciences, 2015, 353, 191-192.	0.3	4

Kenichi Kaida

#	Article	IF	CITATIONS
19	Human herpes virus-8-associated multicentric Castleman's disease in an HIV-positive patient presenting with relapsing and remitting hyponatraemia. International Journal of STD and AIDS, 2015, 26, 909-911.	0.5	Ο
20	Pathogenic roles of antiganglioside antibodies in immuneâ€nediated neuropathies. Clinical and Experimental Neuroimmunology, 2013, 4, 60-69.	0.5	12
21	Efficacy of methylprednisolone pulse therapy for acute relapse in <scp>J</scp> apanese patients with multiple sclerosis and neuromyelitis optica: A multicenter retrospective analysis – 1. Whole group analysis. Clinical and Experimental Neuroimmunology, 2013, 4, 305-317.	0.5	9
22	Nationwide survey of patients in Japan with Bickerstaff brainstem encephalitis: epidemiological and clinical characteristics. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1210-1215.	0.9	74
23	Antibodies to gangliosides and ganglioside complexes in Guillain–Barré syndrome and Fisher syndrome: Mini-review. Journal of Neuroimmunology, 2010, 223, 5-12.	1.1	84
24	Antiganglioside antibodies and their pathophysiological effects on Guillain-Barre syndrome and related disordersA review. Glycobiology, 2009, 19, 676-692.	1.3	138
25	Guillain–Barré syndrome: update on immunobiology and treatment. Expert Review of Neurotherapeutics, 2009, 9, 1307-1319.	1.4	21
26	Ganglioside complexes as target antigens in Guillain–Barré syndrome and related disorders. Future Lipidology, 2008, 3, 425-434.	0.5	3
27	Dysautonomia in immuneâ $\in$ mediated neuropathies. Neurology and Clinical Neuroscience, 0, , .	0.2	0